Patents by Inventor Thomas D. Prevot

Thomas D. Prevot has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • COMPOSITIONS AND METHODS RELATING TO USE OF AGONISTS OF ALPHA5-CONTAINING GABAA RECEPTORS
    Publication number: 20260263478
    Abstract: The invention provides methods and related compositions for preventing neurocognitive decline associated with chronic stress, age, and neurodegenerative diseases. The methods described here are based upon the use of alpha5-GABAA receptor agonists to slow or prevent deleterious morphological changes in dendrites of the hippocampus and prefrontal cortex, which eventually manifest in functional decline and the neurocognitive deficits.
    Type: Application
    Filed: April 30, 2026
    Publication date: September 10, 2026
    Applicant: Centre for Addiction and Mental Health
    Inventors: Thomas D. Prevot, Mounira Banasr, Etienne Sibille
  • EEG BIOMARKERS FOR ALPHA5 PAM DOSAGE DETERMINATION AND THERAPEUTIC MONITORING
    Publication number: 20260253701
    Abstract: The invention provides methods of dosing and monitoring efficacy of GABAA receptor positive allosteric modulators (PAM) therapy, including ?5-PAM therapy, using a patient's power spectral density (PSD) features via non-invasive electroencephalography.
    Type: Application
    Filed: November 6, 2023
    Publication date: August 27, 2026
    Applicant: Centre for Addiction and Mental Health
    Inventors: Etay Hay, Etienne Sibille, Thomas D. Prevot
  • Compositions and methods relating to use of agonists of ALPHA5-containing GABAA receptors
    Patent number: 12636291
    Abstract: The invention provides methods and related compositions for preventing neurocognitive decline associated with chronic stress, age, and neurodegenerative diseases. The methods described here are based upon the use of alpha5-GABAA receptor agonists to slow or prevent deleterious morphological changes in dendrites of the hippocampus and prefrontal cortex, which eventually manifest in functional decline and the neurocognitive deficits.
    Type: Grant
    Filed: February 12, 2020
    Date of Patent: May 26, 2026
    Assignee: Centre for Addiction and Mental Health
    Inventors: Thomas D. Prevot, Mounira Banasr, Etienne Sibille
  • COMPOSITIONS AND METHODS RELATING TO USE OF AGONISTS OF ALPHA5-CONTAINING GABAA RECEPTORS
    Publication number: 20220105106
    Abstract: The invention provides methods and related compositions for preventing neurocognitive decline associated with chronic stress, age, and neurodegenerative diseases. The methods described here are based upon the use of alpha5-GABAA receptor agonists to slow or prevent deleterious morphological changes in dendrites of the hippocampus and prefrontal cortex, which eventually manifest in functional decline and the neurocognitive deficits.
    Type: Application
    Filed: February 12, 2020
    Publication date: April 7, 2022
    Inventors: Thomas D. Prevot, Mounira Banasr, Etienne Sibille